Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2

British Journal of Pharmacology

Volumn 166, Issue 5, 2012, Pages 1694-1707

  Eichenbaum, G ^a   Pugsley, M K ^a   Gallacher, D J ^b   Towart, R ^b   McIntyre, G ^c   Shukla, U ^a   Davenport, J M ^d   Lu, H R ^b   Rohrbacher, J ^b   Hillsamer, V ^a  

^a JOHNSON AND JOHNSON   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Furiex Pharmaceuticals   (United States)

^d Furiex Pharmaceuticals   (United States)

Author keywords

cardiovascular safety; fluoroquinolones; ion channel; JNJ Q2; moxifloxacin; QTc; thorough QT

Indexed keywords

CALCIUM CHANNEL L TYPE; JNJ Q2; MOXIFLOXACIN; OFLOXACIN; PLACEBO; PLASMA PROTEIN; POTASSIUM CHANNEL HERG; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SODIUM CHANNEL; SODIUM CHANNEL NAV1.5; SPARFLOXACIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR PARAMETERS; CELL STRAIN HEK293; CHANNEL GATING; CHO CELL; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOG; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; ELECTROCARDIOGRAPHY; FEMALE; GUINEA PIG; HEART LEFT VENTRICLE; HEART RATE; HEART REPOLARIZATION; HEART RIGHT ATRIUM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RABBIT; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; T WAVE;

ANIMALS; ANTI-BACTERIAL AGENTS; ATRIAL FUNCTION; BLOOD PRESSURE; CALCIUM CHANNELS; CHO CELLS; CRICETINAE; CRICETULUS; CROSS-OVER STUDIES; DOGS; DOUBLE-BLIND METHOD; FEMALE; FLUOROQUINOLONES; GUINEA PIGS; HEART ATRIA; HEART RATE; HEART VENTRICLES; HEK293 CELLS; HUMANS; LONG QT SYNDROME; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; POTASSIUM CHANNELS; RABBITS; SODIUM CHANNELS; VENTRICULAR FUNCTION;

EID: 84862738312     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01874.x     Document Type: Article

References (49)

1. Abraham S, Beatch GN, MacLeod BA, Walker MJ, (1989). Antiarrhythmic properties of tetrodotoxin against occlusion-induced arrhythmias in the rat: a novel approach to the study of the antiarrhythmic effects of ventricular sodium channel blockade. J Pharmacol Exp Ther 251: 1166-1173.
2. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1 -S 324.
3. Antzelevitch C, Belardinelli L, (2006). The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis. J Cardiovasc Electrophysiol 17 (Suppl. 1): S79-S85.
4. Ball P, (2000). Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother 45: 557-559.
5. Bean BP, Cohen CJ, Tsien RW, (1983). Lidocaine block of cardiac sodium channels. J Gen Physiol 81: 613-642.
6. Carlsson L, (2008). The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes. Pharmacol Ther 119: 160-167.
7. Carmeliet E, (1977). Repolarisation and frequency in cardiac cells. J Physiol (Paris) 73: 903-923.
8. Champeroux P, Ouille A, Martel E, Fowler JS, Maurin A, Richard S, et al,. (2011). A step towards characterisation of electrophysiological profile of torsadogenic drugs. J Pharmacol Toxicol Methods 63: 269-278.
9. Chiba K, Sugiyama A, Satoh Y, Shiina H, Hashimoto K, (2000). Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades. Toxicol Appl Pharmacol 169: 8-16.
10. Gellens ME, George AL, Jr, Chen LQ, Chahine M, Horn R, Barchi RL, et al,. (1992). Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel. Proc Natl Acad Sci USA 89: 554-558.
11. Guo L, Dong Z, Guthrie H, (2009). Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates. J Pharmacol Toxicol Methods 60: 130-151.
12. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ, (1981). Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391: 85-100.
13. Ju YK, Saint DA, Gage PW, (1992). Effects of lignocaine and quinidine on the persistent sodium current in rat ventricular myocytes. Br J Pharmacol 107: 311-316.
14. Kang J, Chen XL, Wang H, Ji J, Reynolds W, Lim S, et al,. (2004). Cardiac ion channel effects of tolterodine. J Pharmacol Exp Ther 308: 935-940.
15. Krafte DS, Volberg WA, Rapp L, Kallen RG, Lalik PH, Ciccarelli RB, (1995). Stable expression and functional characterization of a human cardiac Na+ channel gene in mammalian cells. J Mol Cell Cardiol 27: 823-830.
16. Lawrence CL, Pollard CE, Hammond TG, Valentin JP, (2005). Nonclinical proarrhythmia models: predicting Torsades de pointes. J Pharmacol Toxicol Methods 52: 46-59.
17. Liu T, Brown BS, Wu Y, Antzelevitch C, Kowey PR, Yan GX, (2006). Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 3: 948-956.
18. Lu HR, Remeysen P, Somers K, Saels A, De Clerck F, (2001). Female gender is a risk factor for drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model. J Cardiovasc Electrophysiol 12: 538-545.
19. Lu HR, Vlaminckx E, Van de Water A, Rohrbacher J, Hermans A, Gallacher DJ, (2007). In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur J Pharmacol 577: 222-232.
20. Lu HR, Rohrbacher J, Vlaminckx E, Van Ammel K, Yan GX, Gallacher DJ, (2010). Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers. Br J Pharmacol 160: 60-76.
21. Mittelstadt SW, Hart SM, (2005). Effects of moxifloxacin on QT interval in conscious dogs. J Vet Pharmacol Ther 28: 253-256.
22. Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, et al,. (2010). In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother 54: 1955-1964.
23. Morrow BJ, Abbanat D, Baum EZ, Crespo-Carbone SM, Davies TA, He W, et al,. (2011). Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrobial Agents and Chemotherapy 55: 5512-5521.
24. Nerbonne JM, Kass RS, (2005). Molecular physiology of cardiac repolarization. Physiol Rev 85: 1205-1253.
25. Owens RCJ, (2004). QT prolongation with antimicrobial agents: understanding the significance. Drugs 64: 1091-1124.
26. Polak S, Wisniowska B, Brandys J, (2009). Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modelling of drugs' cardiotoxic properties. J Appl Toxicol 29: 183-206.
27. Pollard CE, Abi Gerges N, Bridgland-Taylor MH, Easter A, Hammond TG, Valentin JP, (2010). An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol 159: 12-21.
28. Pugsley MK, Authier S, Curtis MJ, (2008a). Principles of safety pharmacology. Br J Pharmacol 154: 1382-1399.
29. Pugsley MK, Gallacher DJ, Towart R, Authier S, Curtis MJ, (2008b). Methods in safety pharmacology in focus. J Pharmacol Toxicol Methods 58: 69-71.
30. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al,. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and Torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32-45.
31. Rubinstein E, Camm J, (2002). Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 49: 593-596.
32. Sanguinetti MC, Tristani-Firouzi M, (2006). hERG potassium channels and cardiac arrhythmia. Nature 440: 463-469.
33. Savelieva I, Camm J, (2008). Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 10: 647-665.
34. Schneider J, Jahnel U, Linz K, (2010). Neutral effects of the novel analgesic tapentadol on cardiac repolarization due to mixed ion channel inhibitory activities. Drug Dev Res 71: 197-208.
35. Smith DA, Di L, Kerns EH, (2010). The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 9: 929-939.
36. Smith PL, Baukrowitz T, Yellen G, (1996). The inward rectification mechanism of the HERG cardiac potassium channel. Nature 379: 833-836.
37. Snyders DJ, Chaudhary A, (1996). High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol 49: 949-955.
38. Szigligeti P, Banyasz T, Magyar J, Szigeti G, Papp Z, Varro A, et al,. (1998). Intracellular calcium and electrical restitution in mammalian cardiac cells. Acta Physiol Scand 163: 139-147.
39. Takagishi Y, Yasui K, Severs NJ, Murata Y, (2000). Species-specific difference in distribution of voltage-gated L-type Ca(2+) channels of cardiac myocytes. Am J Physiol Cell Physiol 279: C1963-C1969.
40. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA, (1995). HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269: 92-95.
41. Van Deuren B, Van Ammel K, Somers Y, Cools F, Straetemans R, van der Linde HJ, et al,. (2009). The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research. J Pharmacol Toxicol Methods 60: 11-23.
42. Vos MA, (2008). Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced Torsades de pointes liability. Br J Pharmacol 154: 1523-1527.
43. Wang JC, (1996). DNA topoisomerases. Annu Rev Biochem 65: 635-692.
44. Wisialowski T, Crimin K, Engtrakul J, O'Donnell J, Fermini B, Fossa AA, (2006). Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. J Pharmacol Exp Ther 318: 352-359.
45. Yang T, Snyders D, Roden DM, (2001). Drug block of I Kr: model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 38: 737-744.
46. Yap YG, Camm AJ, (2003). Drug induced QT prolongation and Torsades de pointes. Heart 89: 1363-1372.
47. Zhang S, Zhou Z, Gong Q, Makielski JC, January CT, (1999). Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 84: 989-998.
48. Zhou Z, Vorperian VR, Gong Q, Zhang S, January CT, (1999). Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol 10: 836-843.
49. Zuckerman JM, Qamar F, Bono BR, (2009). Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am 23: 997-1026. ix-x.